Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Deferred Taxes: 2022-2025

Historic Deferred Taxes for Harmony Biosciences Holdings (HRMY) over the last 3 years, with Sep 2025 value amounting to -$3.9 million.

  • Harmony Biosciences Holdings' Deferred Taxes rose 19.65% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.4 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of -$29.3 million for FY2024, which is 118.33% down from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Deferred Taxes stood at -$3.9 million, which was up 40.15% from -$6.5 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Deferred Taxes' 5-year high stood at $1.1 million during Q4 2023, with a 5-year trough of -$14.3 million in Q2 2024.
  • For the 3-year period, Harmony Biosciences Holdings' Deferred Taxes averaged around -$5.2 million, with its median value being -$4.3 million (2025).
  • As far as peak fluctuations go, Harmony Biosciences Holdings' Deferred Taxes skyrocketed by 126.34% in 2023, and later tumbled by 697.68% in 2024.
  • Quarterly analysis of 4 years shows Harmony Biosciences Holdings' Deferred Taxes stood at -$4.3 million in 2022, then spiked by 126.34% to $1.1 million in 2023, then plummeted by 697.68% to -$6.7 million in 2024, then climbed by 19.65% to -$3.9 million in 2025.
  • Its last three reported values are -$3.9 million in Q3 2025, -$6.5 million for Q2 2025, and -$4.3 million during Q1 2025.